In particular, patients in the subgroup with CD8Hi/MφHi signatures had further increased expression of immune-related signatures and genes, including those related to T-cell cytotoxicity (CD8A, GNLY, GZMA, GZMB), T-cell trafficking (CXCL9, CXCL10, CCL4, CCL5), and major histocompatibility complex class I (MHC I) (TAP1, TAP2, HLA.A, HLA.B, HLA.C); in contrast, these patients exhibited the lowest expression of tumor proliferation signatures (PLK1, AURKA, CCNB1) (Fig. 3B, C). This evidence concerns the gene CCL5 and neoplasm.